Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Am Heart J. 2012 Oct;164(4):607–615. doi: 10.1016/j.ahj.2012.07.004

Figure 3.

Figure 3

Antithrombotic use according to stroke and bleeding risk. A, The percentage of patients treated with warfarin, antiplatelet therapy alone (aspirin, clopidogrel, or both), and triple therapy (warfarin, aspirin, and clopidogrel) according to CHADS2 and ATRIA scores. B, Warfarin use according to CHADS2 and ATRIA scores in patients aged 65 to 79 years versus patients aged ≥80 years. Within each bar are the number of patients (n) in a given risk category and age group and the percentage of the overall age subgroup that this n represents.*P < .001; **P < .0001; ‡P < .01 for trends across corresponding categories.